Quanterix Co. (NASDAQ:QTRX) Stock Holdings Lifted by Moors & Cabot Inc.

Moors & Cabot Inc. boosted its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 107.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,873 shares of the company’s stock after purchasing an additional 15,992 shares during the period. Moors & Cabot Inc. owned about 0.08% of Quanterix worth $328,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Peapack Gladstone Financial Corp purchased a new position in Quanterix during the third quarter valued at approximately $131,000. Levin Capital Strategies L.P. purchased a new position in Quanterix during the fourth quarter valued at approximately $159,000. Tallon Kerry Patrick acquired a new stake in Quanterix in the fourth quarter valued at approximately $169,000. Intech Investment Management LLC acquired a new stake in Quanterix in the third quarter valued at approximately $170,000. Finally, GSA Capital Partners LLP acquired a new stake in Quanterix in the third quarter valued at approximately $258,000. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Stock Down 0.7 %

NASDAQ QTRX opened at $7.06 on Friday. The stock has a market capitalization of $271.98 million, a PE ratio of -6.66 and a beta of 1.33. The company has a 50 day moving average price of $8.59 and a two-hundred day moving average price of $11.03. Quanterix Co. has a 12-month low of $6.80 and a 12-month high of $27.37.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, December 23rd. The company reported ($0.22) earnings per share (EPS) for the quarter. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, equities analysts anticipate that Quanterix Co. will post -0.98 EPS for the current year.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.